Nexam Chemical Holding AB (publ) Interim Report 1 January – 31 March 2026

The company completed a fully guaranteed rights issue, raising SEK 51.8 million before issue costs. Q1 sales fell 11% year over year, while gross margin held steady at 48%, indicating mixed operating performance. Performance Masterbatch sales were down 1% and Performance Chemicals sales fell 25%, but recycling growth was up 89% in a cautious market.

Analysis

The capital raise is a double-edged signal: it buys time, but it also tells you the market is effectively underwriting working capital and/or a reset of the balance sheet rather than paying for growth. In a low-visibility demand environment, that tends to extend the runway for incumbents with scale while pressuring weaker peers that were relying on share gains through discounting or customer financing. The 89% recycling-growth headline looks more like a mix shift and base effect than evidence of a broad cyclical upturn; the key question is whether volumes can hold once the post-raise liquidity cushion is deployed.

Gross margin holding steady despite weaker top line suggests pricing discipline or favorable input timing, which matters because it implies the company has not yet entered a classic margin-collapse phase. If that discipline persists for another 1-2 quarters, competitors with less pricing power will likely face a binary choice: defend share and burn cash, or protect margins and lose volume. That dynamic usually surfaces first in the middle of the chain, where smaller processors and distributors lose negotiating leverage before the larger strategic accounts move.

The main catalyst set is not immediate demand recovery but balance-sheet repair and customer confidence. A successful rights issue can reduce near-term solvency risk, but if end-market demand does not inflect within 2-3 quarters, the market will reprice the equity around dilution rather than survival. The contrarian view is that this may be a better setup than the headline suggests: in a wait-and-see market, companies that can fund inventory and receivables without distress often emerge with share gains once customers restock, while weaker rivals are forced into price cuts or exits.

Key Decisions for Investors

• Avoid chasing the equity into the rights-issue relief rally; wait 4-8 weeks for post-funding operating evidence before taking risk. If the stock holds after dilution and working capital stabilizes, the setup improves materially.
• Consider a relative-value long/short basket: long better-capitalized specialty/compounding peers, short smaller leveraged processors exposed to the same end markets. The trade should work over 1-3 quarters if pricing discipline holds and weaker names need to discount to preserve volume.
• If options are liquid, buy 3-6 month downside protection on the equity or sector proxy into any rebound. Risk/reward favors hedging because dilution plus demand uncertainty creates a shallow upside case but meaningful downside if growth stalls again.
• Watch for a second-quarter order-book inflection before adding long exposure; a continuation of margin stability with flat-to-up volumes would justify a tactical long, but only with a tight stop on any renewed revenue contraction.
• If the company has credible restructuring or asset-sale optionality, look for a catalyst trade: long only on confirmation of covenant relief or asset monetization, not on headline recycling growth alone.